bpc-157 fda warning letter compounding issued 25 letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of The Food and Drug Administration's

The peptide also influences neurotransmitter systems, particularly dopaminergic and GABAergic pathways, contributing to its neuroprotective effects

Sophisticated peptide therapy requires ongoing partnership, not one-time advice

(CSE: BPC) (OTCQB: PNGAF) announced on July 14, 2026, that it has received its full production run of approximately 20,000 units of its BPC-157 transdermal patch, the company's lead product candidate

Many patients experience significant pain reduction and improved mobility without the long-term side effects of medication

Healthy Gut: Provides insights related to digestive wellness and healthy gut function

Some compounding pharmacies and licensed providers offer it under specific conditions and through physician oversight